uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares

uniQure NV (NASDAQ:QURE) Reports Q2 2025 Earnings: Mixed Results Amid Regulatory Progress

uniQure NV released its second-quarter 2025 financial results, revealing a mixed performance relative to analyst expectations. The company reported revenue of $5.26 million, falling short of the estimated $5.84 million. However, its earnings per share (EPS) of -$0.69 outperformed the consensus estimate of -$0.91, suggesting better-than-anticipated cost management.

Key Financial Takeaways

• Revenue Miss: Reported sales of $5.26M vs. $5.84M estimate, a 10% shortfall.
• EPS Beat: Posted a loss of $0.69 per share, narrower than the projected -$0.91.
• Market Reaction: Shares rose 3.47% in pre-market trading, indicating investor optimism despite the revenue miss.

The positive EPS surprise appears to have outweighed concerns over the revenue underperformance, with the market reacting favorably. Over the past month, QURE has gained 8.08%, reflecting growing confidence in the company’s pipeline progress.

Regulatory and Pipeline Developments

The earnings release highlighted significant progress in uniQure’s clinical programs, particularly for AMT-130, its gene therapy candidate for Huntington’s disease. The company confirmed alignment with the FDA on the statistical analysis plan and Chemistry, Manufacturing, and Controls (CMC) requirements, paving the way for a Biologics License Application (BLA) submission in Q1 2026.

This regulatory milestone is a critical step toward potential approval, reinforcing investor sentiment despite the revenue shortfall.

Forward-Looking Estimates

Looking ahead, analysts expect:

• Q3 2025 Revenue: $5.48M (vs. Q2’s $5.26M)
• Q3 2025 EPS Estimate: -$0.87 (improving from Q2’s -$0.69 actual)
• Full-Year 2025 Revenue Estimate: $21.2M
• Full-Year 2025 EPS Estimate: -$3.64

While the company did not provide explicit guidance in its release, the market appears to be pricing in optimism around its clinical advancements rather than near-term financial performance.

Conclusion

uniQure’s Q2 earnings reflect a company balancing financial challenges with meaningful progress in its gene therapy pipeline. The EPS beat and regulatory advancements for AMT-130 have driven positive market sentiment, overshadowing the revenue miss.

For a deeper dive into uniQure’s earnings and analyst estimates, visit QURE Earnings & Estimates.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.